ProQR to Present at Scientific and Investor Conferences in September
September 06 2016 - 7:00AM
ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to
changing lives through the creation of transformative RNA medicines
for the treatment of severe orphan diseases such as cystic fibrosis
(CF) and Leber's congenital amaurosis Type 10 (LCA10), today
announced that the company will present at a scientific conference
and two investor conferences during the month of September.
Oligonucleotide Therapeutics Society
During the 12th Annual Meeting of the Oligonucleotide
Therapeutics Society (OTS) September 25 – 28, 2016 the company will
present two posters titled: ‘QR-010 Restores CFTR Function in
Models of F508del-mediated Cystic Fibrosis’ and ‘QR-110 Treatment
for Leber’s Congenital Amaurosis Type 10 due to the p.Cys998X
Mutation in CEP290’. The abstracts will be available on the OTS
website prior to the conference. The conference is being held at
the Centre Mont-Royal in Montreal, Quebec, Canada.
LEERINK Partners Roundtable Series: Rare Disease &
Immuno-Oncology
Daniel de Boer, Chief Executive Officer, will take part in an
analyst led fireside chat during the LEERINK Partners
Roundtable Series: Rare Disease & Immuno-Oncology on Wednesday,
September 28, 2016 at 1:35pm ET. The conference is being held at
the Lotte New York Palace in New York, NY, USA.
The live and archived webcast of the presentation will be
accessible from the ‘Investor Relations’ section of ProQR’s website
(www.proqr.com) under ‘Events and Presentations’. The archived
webcast will be available for 30 days following the presentation
date.
Jefferies Cystic Fibrosis Summit
Daniel de Boer, Chief Executive Officer, will present at the
Jefferies Cystic Fibrosis Summit on Thursday, September 29, 2016.
The conference is being held at the Jefferies Conference Center in
New York, NY, USA.
Further details on the presentation will be posted in the
‘Investor Relations’ section of ProQR’s website (www.proqr.com)
under ‘Events and Presentations’.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the
creation of transformative RNA medicines for the treatment of
severe orphan diseases such as cystic fibrosis and Leber’s
congenital amaurosis. Based on our unique proprietary RNA repair
platform technologies we are growing our pipeline with patients and
loved ones in mind. Since 2012.
FORWARD-LOOKING
STATEMENTS
This press release contains forward-looking statements. All
statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions.
Forward-looking statements are based on management’s beliefs and
assumptions and on information available to management only as of
the date of this press release. These forward-looking statements
include, but are not limited to, statements about the OTS
conference, Leerink Partners roundtable and Jefferies CF Summit.
Our actual results could differ materially from those anticipated
in these forward-looking statements for many reasons, including,
without limitation, risks associated with our clinical development
activities, manufacturing processes and facilities, regulatory
oversight, product commercialization, intellectual property claims,
and the risks, uncertainties and other factors in our filings made
with the Securities and Exchange Commission, including certain
sections of our annual report filed on Form 20-F. Given these
risks, uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future.
ProQR Therapeutics N.V.:Sariette WitteHead of
CommunicationsT: +1 213 261 8891ir@proqr.com
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Aug 2024 to Sep 2024
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Sep 2023 to Sep 2024